Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $238.0 million.

  • Arcus Biosciences' Cash & Equivalents rose 1840.8% to $238.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year increase of 1840.8%. This contributed to the annual value of $150.0 million for FY2024, which is 1811.02% up from last year.
  • Per Arcus Biosciences' latest filing, its Cash & Equivalents stood at $238.0 million for Q3 2025, which was up 1840.8% from $248.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Cash & Equivalents ranged from a high of $549.0 million in Q1 2022 and a low of $127.0 million during Q4 2023
  • Over the past 5 years, Arcus Biosciences' median Cash & Equivalents value was $206.0 million (recorded in 2022), while the average stood at $233.3 million.
  • In the last 5 years, Arcus Biosciences' Cash & Equivalents skyrocketed by 47965.72% in 2021 and then plummeted by 5664.85% in 2023.
  • Quarter analysis of 5 years shows Arcus Biosciences' Cash & Equivalents stood at $148.0 million in 2021, then soared by 39.19% to $206.0 million in 2022, then plummeted by 38.35% to $127.0 million in 2023, then rose by 18.11% to $150.0 million in 2024, then soared by 58.67% to $238.0 million in 2025.
  • Its Cash & Equivalents was $238.0 million in Q3 2025, compared to $248.0 million in Q2 2025 and $192.0 million in Q1 2025.